Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients.
Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals) and obicetripib (New Amsterdam Pharma). Other Medicxi assets have been acquired by global pharmaceutical companies, including Villaris Therapeutics (Incyte), MiroBio (Gilead Sciences) and Versanis Bio (Eli Lilly) within the last 12 months.
Francesco De Rubertis, co-founder and partner at Medicxi, said: “Our mission is to support the innovative genius of entrepreneurs by providing the critical capital, expertise and experience that form the all-important ‘bridge’ to pharma. This new fund consolidates Medicxi’s position as a key operating platform for scientific entrepreneurs and drug hunters and is deliberately sized for our investment model. We are grateful to our LPs who are once again supporting us by backing Medicxi’s unique asset-centric strategy and our proprietary platform for value creation.”
Nick Williams, partner at Medicxi, added: “Behind every practice-changing medicine lies a product and a vision for how best to match pharmacology to disease. We are excited to continue developing the best of these visions into valuable products sought after by leading global pharmaceutical companies.”
Giovanni Mariggi, partner at Medicxi, concluded: “With Medicxi IV, we will continue to work with leading scientists and clinicians to create asset-focused companies based on deep domain expertise. Together with our extensive network of drug developers, we will accelerate the development of novel therapies for patients.”